TOMI Environmental Solutions, Inc. Joins Forces With Protak Scientific in Ground Breaking Partnership


BEVERLY HILLS, Calif., Nov. 30, 2017 — TOMI Environmental Solutions, Inc. (“TOMI”) (OTCQX:TOMZ), a global decontamination company that specializes in disinfection/decontamination sales and services, including SteraMist™, a hydrogen peroxide-based mist/fog registered with the U.S. Environmental Protection Agency (“EPA”) for use as a hospital-healthcare disinfectant, announced a new partnership with Protak Scientific Ltd. and its affiliated companies through a signed distributor agreement.TOMI™ has started selling and distributing Protak’s line of Enzymatic Biological Indicator products. Protak is the globally exclusive appointed licensee of thermostable Adenylate Kinase technology, developed over fifteen years by Public Health England, an executive agency of the United Kingdom’s Department of Health and is the only manufacturer of Enzyme Indicators (EIs) for hydrogen peroxide decontamination performance validation in the world. Enzyme Indicator technology offers the pharmaceutical and life sciences market a 60 second quantitative validation process post decontamination treatment vs. the standard in today’s market which is a binary pass/fail with a 7 day wait prior to reusing the treated room or releasing the sterilized products. This time savings in validation and digitized system combined with TOMI's industry leading decontamination time makes TOMI a leader in the life sciences market space, as this one-two punch is unmatched by our competitors. The TOMI operations, logistics and service teams have already been trained on use of the EI’s. This validation option is now available for TOMI clients after SteraMist™ decontamination projects both in the U.S. and abroad. TOMI has the opportunity to offer its clients not simply the best technology on the market for decontaminating spaces but also now has the fastest validation process to prove it.TOMI CEO, Dr. Halden Shane, expressed enthusiasm over this partnership. “There is much synergy with Protak as we are both leaders of innovative technology in our respective fields and we are thrilled to now be able to offer these EI’s as a validation resource. I believe this process could revolutionize how decontamination protocols are validated in the future.”Protak’s CEO Phillip Godden states, “We are thrilled to partner with such a leading and dynamic company to distribute our transformative technology. TOMI Environmental Solutions, Inc. shares our likeminded forward thinking, technology driven ethos of bringing advanced solutions that increase safety and speed to the critical decontamination process. Our combined technologies ensure our customers have the very best decontamination and validation technology in the world today.”About TOMI Environmental Solutions, Inc.TOMI Environmental Solutions, Inc. (OTCQX:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform, which was invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense. BIT™ uses a low percentage Hydrogen Peroxide as its only active ingredient to produce a hydroxyl radical (OH ion), represented by the TOMI™ SteraMist™ brand of products, which produces a germ-killing aerosol that works like a visual non-caustic gas.TOMI’s products are designed to service a broad spectrum of commercial structures including but not limited to hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities (when not in operation), military barracks, police and fire departments, and athletic facilities. TOMI’s products and services have also been used in single-family homes and multi-unit residences.TOMI also develops training programs and application protocols for its clients and is a member in good standing of The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America and The Restoration Industry Association.For additional information, please visit or contact us at [email protected].About Protak Scientific LimitedProtak Scientific Limited is the globally exclusive manufacturer of Enzymatic Biological Indicators for immediate, quantitative decontamination validation. Providing a transformative advance to conventional biological indicator decontamination validation. Accelerating the time taken for incubation of the bacterium from up to seven days to just 60 seconds. In addition, Enzymatic Biological Indicator technology provides a quantitative scale of performance from a single test from less than 2.5 log through to greater than 9 log vs. the current binary yes/no log specific data provided by historic process validation and Enzymatic Biological Indicator technology is self-validating and eliminates the concept of rogue results.The Enzymatic Biological Indicator technology has been developed and researched by the UK’s Department of Health for over fifteen years, with considerable investment and now boasts over sixty patents.The Enzymatic Biological Indicator validation process can be used in almost any setting, from pharma manufacturing through to healthcare, the Enzymatic Biological Indicator product and reader is portable and easy to use; Enzymatic Biological Indicator technology consistently delivers significant savings to all users, saving pharma manufacturers potentially multi-millions of dollars per year and thousands of man hours and in a healthcare setting consistently delivers decontamination process validation immediately, giving a new level of decontamination assurance that is unrivalled by any other technology in todays market place. Protak offers worldwide support and support to multinational companies.Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.MEDIA RELATIONS CONTACTJuliana deRosa
Executive Administrator
[email protected] 

Powered by WPeMatico